Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2–Negative Metastatic Breast Cancer
Sign Up to like & getrecommendations! Published in 2025 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2024.61067
Abstract: Key Points Question Can post–cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy be optimized based on clinicopathologic characteristics in patients with hormone receptor–positive, ERBB2 (formerly HER2 or HER2/neu)–negative metastatic breast cancer? Findings In a cohort study of… read more here.
Keywords: positive erbb2; cdk4; therapy; receptor positive ... See more keywords
Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6‐independent manner
Sign Up to like & getrecommendations! Published in 2017 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12072
Abstract: Palbociclib, a CDK4/6 inhibitor, has recently been approved for hormone receptor‐positive breast cancer patients. The effects of palbociclib as a treatment for other malignancies, including hepatocellular carcinoma (HCC), are of great clinical interest and are… read more here.
Keywords: hepatocellular carcinoma; palbociclib; hcc; pp5 ampk ... See more keywords
TSPAN31 suppresses cell proliferation in human cervical cancer through down‐regulation of its antisense pairing with CDK4
Sign Up to like & getrecommendations! Published in 2020 at "Cell Biochemistry and Function"
DOI: 10.1002/cbf.3526
Abstract: Natural antisense transcripts (NAT) are prevalent phenomena in the mammalian genome and play significant regulatory roles in gene expression. While new insights into NAT continue to be revealed, their exact function and their underlying mechanisms… read more here.
Keywords: human cervical; cell proliferation; cdk4; cervical cancer ... See more keywords
Dependency of Cholangiocarcinoma on Cyclin D–Dependent Kinase Activity
Sign Up to like & getrecommendations! Published in 2019 at "Hepatology"
DOI: 10.1002/hep.30704
Abstract: Cholangiocarcinoma (CCA) is a bile duct cancer with a very poor prognosis. Currently, there is no effective pharmacological treatment available for it. We showed that CCA ubiquitously relies on cyclin‐dependent kinases 4 and 6 (CDK4/6)… read more here.
Keywords: cyclin dependent; cdk4; cholangiocarcinoma; cca ... See more keywords
Circular RNA hsa_circ_0016788 regulates hepatocellular carcinoma tumorigenesis through miR‐486/CDK4 pathway
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Cellular Physiology"
DOI: 10.1002/jcp.26612
Abstract: Recent studies have revealed that circular RNAs (circRNAs) play important roles in the tumorigenesis of human cancer, including hepatocellular carcinoma (HCC). In present study, we screen the circular RNA expression profiles in HCC tissue and… read more here.
Keywords: circ 0016788; hsa circ; cdk4; mir 486 ... See more keywords
CDK4/6 and autophagy inhibitors synergize to suppress the growth of human head and neck squamous cell carcinomas.
Sign Up to like & getrecommendations! Published in 2023 at "Molecular carcinogenesis"
DOI: 10.1002/mc.23556
Abstract: Head and neck squamous cell carcinoma (HNSCC) accounts for over 10,000 deaths in the United States annually. Approximately 80% of HNSCC are human papillomavirus (HPV)-negative which have an overall poorer prognosis compared to the HPV-positive… read more here.
Keywords: cell; head neck; growth; cdk4 ... See more keywords
CDK4, CDK6, cyclin D1, p16(INK4a) and EGFR expression in glioblastoma with a primitive neuronal component
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Neuro-Oncology"
DOI: 10.1007/s11060-017-2674-7
Abstract: Glioblastoma with primitive neuroectodermal tumor-like component (GBM-PNET) is a rare variant of glioblastoma, which was renamed as glioblastoma with a primitive neuronal component (GBM-PN) in new WHO classification of tumours of the central nervous system… read more here.
Keywords: p16 ink4a; component; primitive neuronal; gbm ... See more keywords
Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
Sign Up to like & getrecommendations! Published in 2020 at "Current Oncology Reports"
DOI: 10.1007/s11912-020-00917-8
Abstract: Purpose of Review Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have revolutionized the treatment landscape for patients with hormone receptor-positive (HR+) and HER2-negative (HER2−) metastatic breast cancer (MBC). However, optimal therapy after CDK4/6 inhibitors is… read more here.
Keywords: cdk4 inhibitor; cdk4; breast cancer; cdk4 inhibitors ... See more keywords
CDK4 and CDK5 Inhibition Have Comparable Mild Hypothermia Effects in Preventing Drp1-Dependent Mitochondrial Fission and Neuron Death Induced by MPP+
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Neurobiology"
DOI: 10.1007/s12035-020-02014-0
Abstract: Mild hypothermia has promising effects in the treatment of acute brain insults and also affects cell cycle progression. Mitochondrial dynamics, fusion and fission, are changed along with the cell cycle and disrupted in neurodegenerative diseases,… read more here.
Keywords: hypothermia; mild hypothermia; fission; cdk4 ... See more keywords
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer
Sign Up to like & getrecommendations! Published in 2025 at "Drugs"
DOI: 10.1007/s40265-024-02144-y
Abstract: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have revolutionized the treatment of hormone-receptor positive (HR+), HER2 negative (HER2−) metastatic breast cancer, and are now also established agents in the treatment of high-risk and intermediate-risk HR+ early breast… read more here.
Keywords: breast cancer; treatment; breast; cdk4 ... See more keywords
Genomic Biomarkers Predicting Response to Selective CDK4/6 Inhibition: Progress in an Elusive Search.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer cell"
DOI: 10.1016/j.ccell.2017.11.013
Abstract: In this issue of Cancer Cell, Gong et al. have analyzed the sensitivity of 560 cell lines to the selective CDK4/6 inhibitor abemaciclib and have defined cancers with specific genomic "D-cyclin activating features (DCAF)" as particularly… read more here.
Keywords: predicting response; cdk4; genomic biomarkers; response selective ... See more keywords